RxDoctor Payments Data

Joseph Maglio, MD

Internal Medicine · Granby, CTNPI 1063517282

Payments from drug & device makers

$3,029in general payments, 2019–2025

Across 202 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Abbott$857
  • Amgen$86
  • Dexcom, Inc.$70
  • Pfizer$48
  • E.r. Squibb & Sons, L.L.C.$31
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$3,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,029 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$129,095
Medicare patients
285
Services billed
1,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$111,048
OzempicSemaglutide68$72,684
JardianceEmpagliflozin39$60,197
XareltoRivaroxaban63$58,689
MounjaroTirzepatide49$55,879
JanuviaSitagliptin Phosphate43$55,569
TradjentaLinagliptin40$40,430
RybelsusSemaglutide16$27,996
TrulicityDulaglutide15$23,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,025
MyrbetriqMirabegron17$18,043
Breo ElliptaFluticasone/Vilanterol27$10,690
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,552
Atorvastatin Calcium734$6,448
SynthroidLevothyroxine Sodium65$6,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$111,048122 claims
Novo NordiskOzempic, Rybelsus$17$100,68184 claims
Lilly USA, LLCMounjaro, Trulicity$23$79,69064 claims
Johnson & JohnsonXarelto$17$58,68963 claims
MerckJanuvia$13$55,56943 claims
AbbVieSynthroid, Lumigan$1,855$10,52982 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Granby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →